Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

Although the primary endpoints are toxicity and dose escalation, keep in mind the trials are approved for patients with specific types of hard tumors, that is the trial will use tumor patients and not the usual healthy patients for dose escalation, PK and PD. The secondary endpoint is signs of tumor reduction, i.e. efficacy.

Any efficacy with little toxicity = blown open.